γδ T cells as unconventional targets of checkpoint blockade

Identifying which patients will benefit most from immune checkpoint blockade (ICB) is an important clinical challenge. A study now finds that Vδ1 + γδ T cells are associated with better response to ICB in melanoma tumors with a lower neoantigen load and shows that some effector functions of PD-1 + Vδ1 + T cells are repressed after engagement of PD-1 by PD-L1.